Novel alkylating agent for alkylating target with driver oncogene mutation
AssigneeChiba-Prefecture
InventorsHiroki Nagase, Hiroshi Sugiyama, Toshikazu Bando
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel alkylating agent specifically binding to the genetic mutation site of a driver oncogene. There are provided are a complex formed by binding an alkylating agent to a pyrrole imidazole polyamide specifically binding to the genetic mutation site of a driver oncogene, a driver oncogene mutation-specific alkylating agent comprising the aforementioned complex, and a pharmaceutical composition comprising the aforementioned complex.
Claims19
A complex of an alkylating agent conjugated with DNA-binding compound specifically binding to the genetic mutation site of a driver oncogene,
- wherein the driver oncogene is at least one selected from among KRAS, HRAS, NRAS, BCR-ABL, EGFR, c-KIT, BRAF, PI3K, ALK, PIK3CA, FLT3, MET, BCL2, EML4-ALK, APC, BRCA1/2, TP53, MSH2, MLH1, MSH6, PMS2, RB1, PTEN, VHL, P16, MEN1, RET, CDH1, STK11, PTCH, Her2/neu, EGFR, MYC, MYCN and MET, and also among genes registered in the database of cancer gene mutation;
- and the complex is represented by the following formula:
- or is represented by the following formula:
Dependencies are inferred from the claim text.